Cargando…

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments

Facioscapulohumeral muscular dystrophy (FSHD) represents the third most common form of muscular dystrophy and is characterized by muscle weakness and atrophy. FSHD is caused by the altered expression of the transcription factor double homeobox 4 (DUX4), which is involved in several significantly alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duranti, Elisa, Villa, Chiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253551/ https://www.ncbi.nlm.nih.gov/pubmed/37298453 http://dx.doi.org/10.3390/ijms24119503

Ejemplares similares

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
por: Chen, Jennifer CJ, et al.
Publicado: (2016)

Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy
por: Himeda, Charis L., et al.
Publicado: (2018)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
por: Bosnakovski, Darko, et al.
Publicado: (2017)

A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
por: Jones, Takako, et al.
Publicado: (2018)

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
por: Bouwman, Linde F., et al.
Publicado: (2021)

CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy
por: Das, Sunny, et al.
Publicado: (2021)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy
por: Thijssen, Peter E, et al.
Publicado: (2014)

Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy
por: Šikrová, Darina, et al.
Publicado: (2021)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models
por: Nunes, Andreia M., et al.
Publicado: (2021)

Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
por: Jones, Takako I., et al.
Publicado: (2020)

Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
por: Saad, Nizar Y., et al.
Publicado: (2021)

Treatment of facioscapulohumeral muscular dystrophy with Denosumab
por: Lefkowitz, Stanley S., et al.
Publicado: (2012)

A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
por: Sasaki-Honda, Mitsuru, et al.
Publicado: (2018)

DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021)

A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
por: Campbell, Amy E., et al.
Publicado: (2023)

Multiple Protein Domains Contribute to Nuclear Import and Cell Toxicity of DUX4, a Candidate Pathogenic Protein for Facioscapulohumeral Muscular Dystrophy
por: Corona, Edgardo Daniel, et al.
Publicado: (2013)

RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
por: Mariot, Virginie, et al.
Publicado: (2021)

Cellular and animal models for facioscapulohumeral muscular dystrophy
por: DeSimone, Alec M., et al.
Publicado: (2020)

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2021)

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
por: Greco, Anna, et al.
Publicado: (2020)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
por: Vera, Kathryn, et al.
Publicado: (2020)

Characterizing the face in facioscapulohumeral muscular dystrophy
por: Loonen, T. G. J., et al.
Publicado: (2020)

The socioeconomic burden of facioscapulohumeral muscular dystrophy
por: Blokhuis, Anna M., et al.
Publicado: (2021)

Baroreflex sensitivity in facioscapulohumeral muscular dystrophy
por: Anselmo, Miguel, et al.
Publicado: (2022)

Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials
por: Ghasemi, Mehdi, et al.
Publicado: (2022)

Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy
por: Karpukhina, Anna, et al.
Publicado: (2021)

Nutritional Status of Patients with Facioscapulohumeral Muscular Dystrophy
por: Amzali, Sedda, et al.
Publicado: (2023)

Elderly Onset of Weakness in Facioscapulohumeral Muscular Dystrophy
por: Fee, Dominic B.
Publicado: (2012)

Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy
por: Tasca, Giorgio, et al.
Publicado: (2014)

Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story?
por: Stadler, Guido, et al.
Publicado: (2013)

Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy
por: Bittel, Adam J., et al.
Publicado: (2020)

Cognitive profile of patients with facioscapulohumeral muscular dystrophy
por: dos Santos, Vanessa Brzoskowski, et al.
Publicado: (2021)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Ducharme-Smith, Allison, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r3ccj20sucbiplk0e1u00k1qev